Gareth PowellHead of HealthcareGlobal Healthcare Team
The sector has experienced a relative downturn over the last couple of years but now we are starting to see indications of a potential turning point, believes Gareth. Giving his outlook, Gareth highlights which contrarian market signals are flashing positively for healthcare.
Gareth also discusses valuations, which are at historically low levels across the market-cap spectrum. Combined with long-term drivers such as innovation and elevated utilisation levels, in addition to shorter-term political headwinds dissipating, Gareth concludes that the path forward for healthcare investors looks much clearer.
The sector has experienced a relative downturn over the last couple of years but now we are starting to see indications of a potential turning point, believes Gareth. Giving his outlook, Gareth highlights which contrarian market signals are flashing positively for healthcare.
Gareth also discusses valuations, which are at historically low levels across the market-cap spectrum. Combined with long-term drivers such as innovation and elevated utilisation levels, in addition to shorter-term political headwinds dissipating, Gareth concludes that the path forward for healthcare investors looks much clearer.
Get the latest insights sent straight to your inbox
Gareth Powell, CFA
Gareth joined Polar Capital in 2007 to set up the Healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure.
Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas). As well as this, Gareth worked for the Oxford Business School and various academic laboratories including the Sir William Dunn School of Pathology and the Wolfson Institute for Biomedical Research.
